Gianpiero Fasola
机构: Direttore, Dipartimento di Oncologia, Presidio Ospedaliero Universitario, Azienda Sanitaria
每年引用次数
引用次数
引用: 5,796
H-指数: 40
I10-指数 : 105
出版物: 416
Prognostic value of the interval between the last neoadjuvant chemotherapy (CT) administration and breast surgery: Preliminary data of the NeoBracer international observational study.
Marika Cinausero , Giulia Galli , Debora Basile , Federica Martorana
Journal of Clinical Oncology 36 ( 15_suppl) e12629 -e12629
2018
Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.
Giacomo Pelizzari , Lorenzo Gerratana , Debora Basile , Maria Grazia Vitale
Journal of Clinical Oncology 36 ( 15_suppl) e13079 -e13079
2
2018
Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment
Alessandro Marco Minisini , Jessica Menis , Alessandro Follador , Claudio Avellini
Clinics and Practice 1 ( 2) 33
1
2011
Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report
Gianpiero Fasola , Fabio Puglisi , Alessandro Follador , Marianna Aita
BMC Cancer 6 ( 1) 289 -289
13
2006
Low-Dose Computed Tomography Screening for Lung Cancer and Pleural Mesothelioma in an Asbestos-Exposed Population: Baseline Results of a Prospective, Nonrandomized Feasibility Trial—An Alpe-Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002)
Gianpiero Fasola , Ornella Belvedere , Marianna Aita , Tina Zanin
Oncologist 12 ( 10) 1215 -1224
63
2007
Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature.
Alessandro M. Minisini , Giada Pauletto , Paolo Bergonzi , Gianpiero Fasola
Breast Cancer Research and Treatment 105 ( 2) 133 -138
14
2007
Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC).
Lee Steven Schwartzberg , Fernando Rivera , Meinolf Karthaus , Gianpiero Fasola
Journal of Clinical Oncology 31 3631 -3631
25
2013
The impact of prior chemotherapy (PrC) on immunotherapy outcomes in non-small cell lung cancer (NSCLC) patients: Real data from a mono-institutional study.
Marianna Macerelli , Simona Rizzato , Marco Giavarra , Francesca Valent
Journal of Clinical Oncology 38 ( 15_suppl) e21639 -e21639
2020
Cancer of unknown primary origin: a case report
Elisa De Carlo , Ciro Rossetto , Gianpiero Fasola
Clinical Management Issues 7 ( 1) 27 -34
2013
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
Marianna Aita , Carlotta Defferrari , Francesco Rosetti , Annalisa Brianti
Oncologist 14 ( 5) 497 -510
56
2009
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real‐World Scenario
Marta Bonotto , Lorenzo Gerratana , Elena Poletto , Pamela Driol
Oncologist 19 ( 6) 608 -615
113
2014
Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?
Marta Bonotto , Lorenzo Gerratana , Donatella Iacono , Alessandro Marco Minisini
Oncologist 20 ( 7) 719 -724
34
2015
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
Manuela Miscoria , Fabrizio Tonetto , Laura Deroma , Piernicola Machin
Anti-Cancer Drugs 23 ( 3) 326 -334
13
2012
P-29 Phase II study of irinotecan plus docetaxel in previously treated non-small cell lung cancer (NSCLC) patients: preliminary results. An Alpe Adria thoracic oncology multidisciplinary group study (ATOM 007)
Gianpiero Fasola , Ornella Belvedere , Riccardo Spizzo , Angela Sibau
Lung Cancer 41
3
2003
P-183 Post-operative thoracic radiation therapy (TRT) in radically resected, chemonaive IIIA N2 non-small cell lung cancer (NSCLC) patients: an Alpe Adria Thoracic Oncology Multidisciplinary group study (ATOM 010)
Tino Ceschia , Ornella Belvedere , Francesca Valent , Ciro Rossetto
Lung Cancer 41 ( 41)
2003
Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor Cells.
Matteo Turetta , Michela Bulfoni , Giulia Brisotto , Gianpiero Fasola
Cancers 10 ( 8) 270
7
2018
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker.
Giacomo Pelizzari , Debora Basile , Silvia Zago , Camilla Lisanti
Cancers 11 ( 9) 1243
39
2019
Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014)
Francesco Grossi , Riccardo Spizzo , Domenico Bordo , Veronica Cacitti
Journal of Thoracic Oncology 5 ( 9) 1354 -1360
20
2010
Adopting integrated care pathways in non-small-cell lung cancer: from theory to practice.
Gianpiero Fasola , Simona Rizzato , Valentina Merlo , Marianna Aita
Journal of Thoracic Oncology 7 ( 8) 1283 -1290
17
2012
Factors affecting patient's perception of anticancer treatments side-effects: an observational study
Stefania Russo , Marika Cinausero , Lorenzo Gerratana , Claudia Bozza
Expert Opinion on Drug Safety 13 ( 2) 139 -150
16
2014